Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Companies eye slice of age-related macular degeneration market

Nature Biotechnology volume 24, pages 1041–1042 (2006)Cite this article

Genentech has the first treatment that restores sight in patients with AMD, but it may face competition from one of its own drugs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. New York

    Emily Waltz

Authors
  1. Emily Waltz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waltz, E. Companies eye slice of age-related macular degeneration market. Nat Biotechnol 24, 1041–1042 (2006). https://doi.org/10.1038/nbt0906-1041

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0906-1041

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing